脯氨酸羟化酶3在乳腺癌中的表达及其对乳腺癌细胞恶性表型的影响

摘要
图/表
参考文献(25)
相关文章 (15)

全文: PDF (981 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究脯氨酸羟化酶3（EGLN3）在乳腺癌中的表达情况及功能。方法使用GEPIA网站，分析EGLN3在TCGA和GTEx数据库中1085例乳腺癌组织和291例正常组织样本中的表达。选取2010年1月至2017年12月中国医学科学院北京协和医学院肿瘤医院诊治的52例乳腺癌患者的癌组织和癌旁组织，采用real-time PCR方法检测EGLN3 mRNA的表达水平。Western blot法检测EGLN3蛋白在正常乳腺上皮细胞（MCF-10A）和11株乳腺癌细胞（ZR-75-1、SK-BR-3、MDA-MB-453、BT474、MCF-7、T47D、MDA-MB-231、CAL-51、HS578T、MDA-MB-468、HCC1937）中的表达情况。采用xCELLigence RTCA MP系统、克隆形成实验和Transwell实验分别检测转染siRNA敲降EGLN3后对乳腺癌细胞增殖、克隆形成、侵袭和迁移能力的影响。结果乳腺癌组织EGLN3 mRNA表达高于正常组织，差异有统计学意义（P ＜ 0.05）。乳腺癌组织EGLN3 mRNA表达高于癌旁组织，差异有高度统计学意义（P ＜ 0.01）。EGLN3蛋白在乳腺癌细胞MDA-MB-231、CAL-51、MDA-MB-468和HCC1937中高表达，而在正常乳腺上皮细胞及其他乳腺癌细胞中不表达。转染siRNA敲降EGLN3后，乳腺癌细胞的增殖、克隆形成能力、侵袭和迁移能力均降低。结论 EGLN3表达可能与乳腺癌的发生发展有关，下调EGLN3可抑制乳腺癌细胞的恶性表型，但其机制需进一步研究。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王杨1 赵梓彤2 宋咏梅2 张柏林1

关键词 ：脯氨酸羟化酶3, 乳腺癌, 增殖, 侵袭, 迁移

Abstract：Objective To investigate the expression and function of the Egl nine homolog 3 (EGLN3) in breast cancer. Methods The expression of EGLN3 in 1085 cases of breast cancer tissues and 291 cases of normal tissues from the TCGA and GTEx databases was analyzed by using GEPIA website. A total of 52 cases of breast cancer tissues and adjacent tissues were collected in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College from January 2010 to December 2017. The EGLN3 mRNA expression in breast cancer tissues was detected by real-time PCR. EGLN3 protein expression in normal breast epithelial cell (MCF-10A) and 11 cell lines of breast cancer (ZR-75-1, SK-BR-3, MDA-MB-453, BT474, MCF-7, T47D, MDA-MB-231, CAL-51, HS578T, MDA-MB-468, HCC1937) were detected by Western blot. The effect of transfection siRNA knockdown EGLN3 on proliferation, clonal formation, invasion and migration of breast cancer cells were detected by xCELLigence RTCA MP system, clonal formation assay and Transwell assay, respectively. Results The expression of EGLN3 mRNA in breast cancer tissues was higher than that in normal tissues， and the difference was statistically significant (P < 0.05). The expression of EGLN3 mRNA in breast cancer tissues was higher than that in adjacent tissues, and the difference was highly statistically significant (P < 0.01). EGLN3 protein was highly expressed in breast cancer cells MDA-MB-231, CAL-51, MDA-MB-468, and HCC1937, but not in normal breast epithelial cells and other breast cancer cells. After transfection with siRNA knockdown EGLN3, the proliferation, clonal formation, invasion and migration of breast cancer cells were decreased. Conclusion EGLN3 expression may be related to the occurrence and development of breast cancer, and down-regulation of EGLN3 can inhibit the malignant phenotype of breast cancer cells, but its mechanism needs further study.

Key words： Egl nine homolog 3 Breast cancer Proliferation Invasion Migration

基金资助:国家自然科学基金资助项目（81872398）。

通讯作者: 张柏林（1968.11-），男，博士，副主任医师，主要从事乳腺癌外科治疗。

作者简介: 王杨（1990.2-），男，硕士，主要从事乳腺癌基础研究。

引用本文:

王杨1 赵梓彤2 宋咏梅2 张柏林1. 脯氨酸羟化酶3在乳腺癌中的表达及其对乳腺癌细胞恶性表型的影响[J]. 中国医药导报, 2021, 18(28): 8-12,34.
WANG Yang1 ZHAO Zitong2 SONG Yongmei2 ZHANG Bailin1. Expression of Egl nine homolog 3 in breast cancer and its effect on malignant phenotype of breast cancer cells. 中国医药导报, 2021, 18(28): 8-12,34.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I28/8

[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Bertucci F，Ng CKY，Patsouris A，et al. Genomic characterization of metastatic breast cancers [J]. Nature，2019， 569（7757）：560-564.
[3] Xu Y，Gao Q，Xue Y，et al. Prolyl hydroxylase 3 stabilizes the p53 tumor suppressor by inhibiting the p53-MDM2 interaction in a hydroxylase-independent manner [J]. J Biol Chem，2019，294（25）：9949-9958.
[4] Xue J，Li X，Jiao S，et al. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity [J]. Gastroenterology，2010，138（2）：606-615.
[5] Place TL，Fitzgerald MP，Venkataraman S，et al. Aberrant promoter CpG methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells [J]. PLoS One，2011，6（1）：e14617.
[6] Hatzimichael E，Dasoula A，Shah R，et al. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia [J]. Eur J Haematol，2010， 84（1）：47-51.
[7] Dopeso H，Jiao HK，Cuesta AM，et al. PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFα [J]. Cancer Res，2018，78（7）：1805-1819.
[8] D’Angelo G，Duplan E，Boyer N，et al. Hypoxia up-regulates prolyl hydroxylase activity：a feedback mechanism that limits HIF-1 responses during reoxygenation [J]. J Biol Chem，2003，278（40）：38183-38187.
[9] Semenza GL. Oxygen sensing，homeostasis，and disease [J]. N Engl J Med，2011，365（6）：537-547.
[10] Morfoisse F，Kuchnio A，Frainay C，et al. Hypoxia induces VEGF-C expression in meta-static tumor cells via a HIF-1α-independent translation-mediated mechanism [J]. Cell Rep，2014，6（1）：155-167.
[11] Luo W，Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells [J]. Oncotarget，2011，2（7）：551-556.
[12] Zhang S，Zhou X，Wang B，et al. Loss of VHL expression contributes to epithelial-mesenchymal transition in oral squamous cell carcinoma [J]. Oral Oncol，2014，50（9）：809-817.
[13] Appelhoff RJ，Tian YM，Raval RR，et al. Differential function of the prolyl hydroxylases PHD1，PHD2，and PHD3 in the regulation of hypoxia-inducible factor [J]. J Biol Chem，2004，279（37）：38458-38465.
[14] Bruick RK，McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF [J]. Science，2001，294（5545）：1337-1340.
[15] Luo W，Lin B，Wang Y，et al. PHD3-mediated prolyl hydroxylation of nonmuscle actin impairs polymerization and cell motility [J]. Mol Biol Cell，2014，25（18）：2788-2796.
[16] Garvalov BK，Foss F，Henze AT，et al. PHD3 regulates EGFR internalization and signal-ling in tumours [J]. Nat Commun，2014，5：5577.
[17] Metzen E，Berchner-Pfannschmidt U，Stengel P，et al. Intracellular localisation of human HIF-1 alpha hydroxylases：implications for oxygen sensing [J]. J Cell Sci，2003，116（Pt 7）：1319-1326.
[18] Jaakkola PM，Rantanen K. The regulation，localization，and functions of oxygen-sensing prolyl hydroxylase PHD3 [J]. Biol Chem，2013，394（4）：449-457.
[19] Egners A，Rezaei M，Kuzmanov A，et al. PHD3 Acts as Tumor Suppressor in Mouse Osteosarcoma and Influences Tumor Vascularization via PDGF-C Signaling [J]. Cancers（Basel），2018，10（12）：496.
[20] Henze AT，Garvalov BK，Seidel S，et al. Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR [J]. Nat Commun，2014，5：5582.
[21] Tang LR，Wu JX，Cai SL，et al. Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1α [J]. Onco Targets Ther，2018，11：8507-8515.
[22] Jiang L，Liu QL，Liang QL，et al. Association of PHD3 and HIF2α gene expression with clinicopathological characteristics in human hepatocellular carcinoma [J]. Oncol Lett，2018，15（1）：545-551.
[23] H?觟gel H，Rantanen K，Jokilehto T，et al. Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells [J]. PLoS One，2011，6（11）：e27112.
[24] Chiba N，Sunamura M，Nakagawa M，et al. Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer [J]. Am J Cancer Res，2020，10（8）：2570-2581.
[25] Subik K，Lee JF，Baxter L，et al. The Expression Patterns of ER，PR，HER2，CK5/6，EGFR，Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines [J]. Breast Cancer（Auckl），2010，4：35-41.